BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. is expanding its private placement offering from CAD $500,000 to CAD $1,000,000, aiming to bolster working capital and advance its acquisition of immunological assets. Additionally, the company plans to convert CAD $773,600 of debt into equity, a move endorsed by the board to improve financial flexibility and involve transactions with related parties exempted from certain regulatory requirements.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
